Albany Molecular Research (AMRI) and Chai Therapeutics, an affiliate of Bessor Pharma, have signed a licensing deal to develop tubulin inhibitor compound, ALB 109564(a), for cancer treatment. AMRI's ALB 109564(a) is a novel analog ...
Albany Molecular Research (AMRI) has reported a net loss of $2.14m, or $0.07 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.85m, or $0.19 per share, for the third quarter ended 30 September 2011. ...